title: Low intracellular ATP levels exacerbate carcinogen-induced inflammatory stress response and inhibit in vitro tubulogenesis in human brain endothelial cells.
abstract: Solid tumor development requires angiogenesis and is correlated to the expression of inflammatory markers through cellular metabolic and energetic adaptation. While high glycolysis rates enable the cancer cell compartment to generate adenosine triphosphate (ATP), very little is known about the impact of low intracellular ATP concentrations within the vascular endothelial cell compartment, which is responsible for tumor angiogenesis. Here, we investigated the effect of 2-deoxy-D-glucose (2-DG), a glucose analog that inhibits glycolysis through intracellular ATP depletion, on human brain microvascular endothelial cell (HBMEC) angiogenic properties. While preformed capillaries remained unaffected, we found that in vitro tubulogenesis was dose-dependently decreased by 2-DG and that this correlated with reduced intracellular ATP levels. Procarcinogenic signaling was induced with phorbol 12-myristate 13-acetate (PMA) and found to trigger the proinflammatory marker cyclooxygenase-2 (COX-2) and endoplasmic reticulum (ER) stress marker GRP78 expression, whose inductions were potentiated when PMA was combined with 2-DG treatment. Inversely, PMA-induced matrix-metalloproteinase-9 (MMP-9) gene expression and protein secretion were abrogated in the presence of 2-DG, and this can be partially explained by reduced nuclear factor-κB signaling. Collectively, we provide evidence for an intracellular ATP requirement in order for tubulogenesis to occur, and we link increases in ER stress to inflammation. A better understanding of the metabolic adaptations of the vascular endothelial cells that mediate tumor vascularization will help the development of new drugs and therapies.
authors.affiliation: Laboratoire d'Oncologie Moléculaire, Centre de Recherche BioMED, Département de Chimie, Université du Québec à Montréal, Montréal, Québec, Canada.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Tahanian
authors.forename: Sabrina
authors.initials: S
authors.lastname: Peiro
authors.forename: Borhane
authors.initials: B
authors.lastname: Annabi
references.citation: Am J Physiol. 1988 Feb;254(2 Pt 2):H223-9
references.pmid: 3344813
references.citation: Brain Res. 1996 Mar 25;713(1-2):64-9
references.pmid: 8724976
references.citation: Neuron. 1993 Aug;11(2):371-86
references.pmid: 8352945
references.citation: Am J Physiol. 1990 Mar;258(3 Pt 2):H689-94
references.pmid: 2316683
references.citation: Semin Cell Dev Biol. 2008 Feb;19(1):52-60
references.pmid: 17625931
references.citation: Int J Cancer. 2005 Jul 20;115(6):849-60
references.pmid: 15729716
references.citation: Brain Res. 2009 Jul 28;1282:142-55
references.pmid: 19477169
references.citation: Cancer Res. 2002 Jan 15;62(2):381-5
references.pmid: 11809684
references.citation: J Clin Invest. 1995 Feb;95(2):738-44
references.pmid: 7860755
references.citation: Angiogenesis. 2010 Sep;13(3):227-38
references.pmid: 20694744
references.citation: Vet Comp Oncol. 2007 Mar;5(1):1-13
references.pmid: 19754797
references.citation: Cell. 1996 Aug 9;86(3):353-64
references.pmid: 8756718
references.citation: Exp Cell Res. 2003 Dec 10;291(2):363-76
references.pmid: 14644158
references.citation: J Neuroimmunol. 1997 Jun;76(1-2):81-90
references.pmid: 9184636
references.citation: Brain Pathol. 2005 Oct;15(4):327-41
references.pmid: 16389945
references.citation: Radiology. 2007 Apr;243(1):105-11
references.pmid: 17329684
references.citation: Mol Nutr Food Res. 2008 Jun;52(6):692-700
references.pmid: 18435488
references.citation: J Biol Chem. 2007 Mar 16;282(11):8142-9
references.pmid: 17229722
references.citation: BMC Cancer. 2009 Jun 30;9:215
references.pmid: 19566920
references.citation: Cancer Lett. 2009 Sep 8;282(1):87-97
references.pmid: 19345476
references.citation: J Clin Pathol. 2002 Jun;55(6):429-34
references.pmid: 12037025
references.citation: Arch Oral Biol. 2009 Oct;54(10):932-42
references.pmid: 19712927
references.citation: Cancer Lett. 2013 May 28;332(2):249-64
references.pmid: 20732741
references.citation: Drug Discov Today. 2002 Mar 15;7(6):364-72
references.pmid: 11893545
references.citation: Nat Biotechnol. 2002 Mar;20(3):243-9
references.pmid: 11875424
references.citation: Mol Carcinog. 2007 Aug;46(8):705-10
references.pmid: 17546626
references.citation: Carcinogenesis. 2010 Mar;31(3):334-41
references.pmid: 20028726
references.citation: Histopathology. 2008 Dec;53(6):698-706
references.pmid: 19102009
references.citation: FASEB J. 1998 Sep;12(12):1063-73
references.pmid: 9737710
references.citation: Cancer Res. 2008 Jan 15;68(2):498-505
references.pmid: 18199545
references.citation: Infect Immun. 1998 Nov;66(11):5260-7
references.pmid: 9784531
references.citation: Cancer Lett. 2009 Jul 8;279(2):171-6
references.pmid: 19264392
references.citation: Oncol Rep. 2009 Mar;21(3):821-6
references.pmid: 19212645
references.citation: J Neuroinflammation. 2010 Nov 30;7:86
references.pmid: 21118574
references.citation: Cancer Biol Ther. 2006 Nov;5(11):1539-45
references.pmid: 17102591
references.citation: Genes Dev. 2010 Aug 15;24(16):1709-17
references.pmid: 20713516
references.citation: Cancer Chemother Pharmacol. 2011 Apr;67(4):899-910
references.pmid: 20593179
references.citation: Int J Oncol. 2004 Nov;25(5):1407-14
references.pmid: 15492832
references.citation: Lasers Surg Med. 2010 Apr;42(4):338-47
references.pmid: 20432283
references.citation: Chem Biol Drug Des. 2010 May;75(5):481-8
references.pmid: 20486934